The goal of this observational registry is to characterize the clinical features, severity, treatments, and outcomes of patients with atopic dermatitis in Costa Rica receiving systemic and advanced therapies in routine clinical practice. The main questions it aims to answer are:
What are the demographic and clinical characteristics of patients with moderate-to-severe atopic dermatitis treated in specialized dermatology centers in Costa Rica?
What treatments are used in real-world practice and how do they impact disease severity and patient-reported outcomes over time?
Participants with atopic dermatitis receiving systemic or advanced therapies as part of their usual medical care will be followed longitudinally, with collection of clinical severity scores, treatment patterns, and outcomes during routine visits.

开始日期2026-05-01

申办/合作机构-

NCT06899204

/ RecruitingN/A

A Prospective, Multi-center Observational Study Characterizing Clinical Outcomes of Patients Receiving Abrocitinib for Moderate-to-severe Atopic Dermatitis Who Had an Inadequate Response (or Intolerance) to ≤2 Previous Biologic Therapies Approved for Moderate-to-severe Atopic Dermatitis

This is a prospective, multi-center observational study characterizing clinical and patient reported outcomes of patients receiving abrocitinib for moderate-to-severe atopic dermatitis (M2S AD) who had inadequate response (or intolerance) to ≤2 previous biologic therapies approved for M2S AD in the United States.
The aim of this study is to measure the effectiveness of abrocitinib in a real-world setting in patients with moderate-to-severe atopic dermatitis, with inadequate response or intolerance to ≤2 biologic therapies.

开始日期2026-01-13

申办/合作机构

Pfizer Inc.

NCT07242638

/ Recruiting临床2期IIT

Use of Specific JAK Inhibition on Inflammatory Skin and Scalp Diseases in Down Syndrome R61AR084210

This is a single-center, open-label, basket phase 2b trial that will enroll Down Syndrome (DS) participants with at least one inflammatory skin condition (Atopic Dermatitis (AD) and/or Alopecia Areata (AA)). Patients will receive Abrocitinib 100 mg daily for 12 weeks. Responders (defined as achieving Eczema Area and Severity Index (EASI) 75 response for AD, or SALT <= 20 for AA) will be kept on this dose, and non-responders based on these definitions, will initiate 200 mg daily for another 12 weeks. All AD and AA patients will be maintained on the respective dose of Abrocitinib from Week 24 through week 60.

开始日期2026-01-12

申办/合作机构

Icahn School of Medicine at Mount Sinai

100 项与阿布昔替尼相关的临床结果

登录后查看更多信息

100 项与阿布昔替尼相关的转化医学

登录后查看更多信息

100 项与阿布昔替尼相关的专利（医药）

登录后查看更多信息

507

项与阿布昔替尼相关的文献（医药）

2026-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Dose-dependent effectiveness and patient-reported outcomes with JAK1 inhibitors in atopic dermatitis: a 36-week multicenter real-world cohort

Article

作者: Ulutaş Demirbaş, Gözde ; Esen, Mustafa ; Diremsizoglu, Esin ; Demirbaş, Abdullah

BACKGROUND:

Dose-stratified real-world data for JAK1 inhibitors in AD are limited.

OBJECTIVE:

To compare effectiveness and safety of standard vs high doses of abrocitinib and upadacitinib in routine care.

METHODS:

Multicenter, retrospective cohort study. The primary endpoint was Week-12 achievement of Eczema Area and Severity Index (EASI)-75. Secondary outcomes included patient-reported improvements at Minimal Clinically Important Difference (MCID) thresholds, Minimal Disease Activity (MDA) at Week 36, time-to-EASI-75, and treatment-emergent adverse events(TEAE).

RESULTS:

A total of 124 patients were analyzed (abrocitinib 100 mg, n = 28; abrocitinib 200 mg, n = 32; upadacitinib 15 mg, n = 30; upadacitinib 30 mg, n = 34). At Week 12, EASI-75 was achieved in 20/32 (62.5%) versus 10/28 (35.7%) for abrocitinib (OR 2.94, 95% CI 1.06-8.15; p = 0.036) and in 22/34 (64.7%) versus 14/30 (46.7%) for upadacitinib (OR 2.92, 95% CI 1.16-7.38; p = 0.021), favoring the higher-dose regimens. Itch improvement was more frequent with higher doses. By Week 36, full minimal disease activity was observed in 30.2% of patients receiving abrocitinib 200 mg and 26.7% receiving upadacitinib 30 mg, compared with 18.4% and 20.0% in the lower-dose groups. Kaplan-Meier analysis showed faster responses with high doses (median 12 vs 36 weeks; log-rank p < 0.01). Safety was comparable across groups.

CONCLUSION:

High-dose JAK1 regimens achieve faster, numerically greater disease control without short-term safety tradeoffs, supporting escalation in suboptimal responders.

2026-12-31·JOURNAL OF MEDICAL ECONOMICS

Cost-utility and budget impact analysis of dupilumab and oral Janus kinase (JAK) inhibitors for treating moderate-to-severe atopic dermatitis in Taiwan

Article

作者: Lee, John Tayu ; Wu, David Bin-Chia ; Shen, Toby Kai-Bo ; Tan, Hsiao-Hsiao ; Yang, Rachel Ai-Ting ; Liu, Valerie Tzu-Ning ; Wang, Yen Hsiang

BACKGOROUND:

Atopic dermatitis (AD), a chronic inflammatory skin disease, affects 1.28% of Taiwan's population, with 26.69% having moderate-to-severe cases, causing significant healthcare costs and quality-of-life impairments. Conventional treatments often fail these patients, necessitating novel therapies like dupilumab and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib, upadacitinib). This study evaluates the cost-utility and budget impact of these therapies versus best supportive care (BSC) for adults with moderate-to-severe AD from Taiwan's NHI perspective.

METHODS:

A hybrid decision tree-Markov model assessed short- and long-term (Years 1-20) outcomes using trial efficacy, NHI costs (2022 NT$), and EQ-5D utilities. Interventions included topical corticosteroids/calcineurin inhibitors. Outcomes were quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs), discounted at 3%, with a NT$2,000,000/QALY threshold. Sensitivity analyses tested robustness. A five-year (2026-2030) budget impact analysis (BIA) included epidemiology and market uptake.

RESULTS:

Upadacitinib 30 mg was most cost-effective (11.0782 QALYs, ICER NT$1,250,903/QALY vs BSC), followed by Upadacitinib 15 mg (NT$1,376,435/QALY). Dupilumab was dominated; Baricitinib's ICERs exceeded NT$2,000,000/QALY. Sensitivity analyses confirmed robustness, with utility gains, medication costs, and discontinuation rates as key drivers. The BIA estimated a NT$117 billion incremental impact, driven by drug costs, with per-patient increments falling from NT$339,769 to NT$264,728.

CONCLUSION:

Upadacitinib 30 mg was the most cost-effective option for moderate-to-severe atopic dermatitis in Taiwan, but its high budget impact underscores the need for strategic pricing and reimbursement policies to ensure long-term affordability and access.

2026-03-02·Dermatitis

Decision-Making Factors for Systemic Therapies in Atopic Dermatitis: A Clinical Review.

Review

作者: Mehta, Apoorva ; Guttman-Yassky, Emma ; O'Hagan, Ross ; Lamb, Angela J ; Levine, Jasmine

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that significantly impairs quality of life. In recent years, treatment has advanced from broad immunosuppressants to targeted biologics and small-molecule therapies that modulate type 2 inflammation and itch signaling. Dupilumab, tralokinumab, lebrikizumab, and nemolizumab are now FDA-approved biologics with demonstrated efficacy and favorable long-term safety, while oral Janus kinase inhibitors (JAKis) such as abrocitinib, upadacitinib, and baricitinib often provide rapid disease control but carry black-box warnings. Comparative trials highlight faster itch relief with JAKis but durable disease control and safety advantages with biologics. The expanding treatment landscape necessitates individualized therapy selection. Key clinical considerations include patient age, pregnancy status, infection, malignancy, or thromboembolic risk, comorbid conditions, and history of adverse effects. Equally important are patient-centered preferences such as dosing frequency, route of administration, storage logistics, and willingness to self-inject. Access and affordability also influence care, with many manufacturers offering copay support and patient assistance programs. Future directions emphasize head-to-head comparative studies, biomarker development for precision treatment, and equitable access to advanced therapies. This narrative review synthesizes current evidence on biologics and JAKis in AD, outlining efficacy, safety, and practical decision-making factors to guide dermatologists in aligning therapies with both clinical context and patient priorities.

450

项与阿布昔替尼相关的新闻（医药）

2026-03-31
·特应性皮炎药媒

国产新药卖了3个亿！司普奇拜单抗VS达必妥，中重度皮炎患者怎么选？

一款新药上市首年就能卖超3亿元，这在医药圈可不是小数字。司普奇拜单抗（商品名：康悦达）做到了。2025年全年销售额3.15亿元，同比增长775%，这背后是无数中重度特应性皮炎患者实实在在的选择。今天我们就来聊聊这款国产新药，以及它和达必妥（度普利尤单抗）到底该怎么选。司普奇拜单抗销售数据根据康诺亚业绩报告，司普奇拜单抗2025年销售额为3.15亿元，较2024年增长775%。该药于2024年9月获批上市，首年表现超出预期。2025年上半年销售额为1.69亿元，下半年持续放量，主要得益于医保覆盖的落地。这款药由康诺亚自主研发，靶点是白介素4受体α亚基（IL-4Rα），是目前国内首款获批上市的国产IL-4Rα单抗。除了治疗成人中重度特应性皮炎，它还被批准用于慢性鼻窦炎伴鼻息肉和季节性过敏性鼻炎，后两项目前是独家适应症，其他同类产品还没有获批。司普奇拜与度普利尤医保价格这是很多患者最关心的。两款药都已纳入国家医保目录，但具体价格差异不小。 l 司普奇拜单抗（康悦达）：300mg/支的医保支付价是1039元。按职工医保70%-80%报销比例计算，每针自付约208-312元，一年下来大约需要自付0.54-0.81万元。 l 度普利尤单抗（达必妥）：300mg/支医保谈判后价格约1508元。同样按70%-80%报销比例，每针自付约300-450元，年自付约0.78-1.17万元。也就是说，在医保报销后，司普奇拜单抗每针比达必妥便宜大约100-150元，一年下来能省几千块钱。对于需要长期用药的患者来说，这笔账还是值得算一算的。不过各地医保报销比例有差异，具体自付金额建议咨询当地医保部门或医院药房。用法用量：给药方案基本一致两款药物均为皮下注射，用法用量高度相似。 l 初始剂量：首次600mg，分两次300mg注射，不同部位。 l 维持剂量：每两周一次，每次300mg。 l 全年注射次数：约26次。注射部位建议在腹部、大腿或上臂轮换。有研究提示，司普奇拜单抗应答较好的患者，后续可将给药间隔延长至四周或八周，但仍需医生评估。往期相关：特皮打针怕麻烦？司普奇拜预充式注射笔在家就能用，一文讲清注射步骤研发企业：国产与进口的差异 l 司普奇拜单抗：由康诺亚自主研发，2024年9月获批，是国内首款获批上市的国产IL-4Rα单抗，目前适应症覆盖（包括慢性鼻窦炎伴鼻息肉、过敏性鼻炎等）。康诺亚还有CM512（TSLP/IL-13双抗）等多款在研管线，后续产品值得关注。 l 度普利尤单抗：达必妥由赛诺菲和再生元联合开发，2017年就在美国获批，是全球第一款IL-4Rα单抗，2020年进入中国，目前适应症覆盖（包括儿童、结节性痒疹、哮喘等）。最后提醒一下，所有治疗决策请务必在专业医生指导下进行，不要自行换药或调整剂量。欢迎在评论区分享你的用药经历或疑问。同靶点新药招募赛诺菲OX40L 单抗，司普奇拜单抗、达必妥头对头等多种靶点生物制剂正在三甲医院开展临床。临床是由国家药监局审批通过，三甲医院专家随访，符合条件用药、体检均不收费，有一定补贴！招募详情： 1.【上市在即】达必妥同靶点新药611临床招募中，12-18岁青少年特应性皮炎患者注意 2.无安慰剂！【头对头】达必妥与特应性皮炎新药GS101临床招募启动，全国三甲可报名三甲医院点击直接报名进患者群真实反馈资讯 ▼ 往期精彩回顾 ▼ 1.临床流程：参与临床试验全流程提前揭晓，让您安心每一步 2.真实案例：【实测】特应性皮炎烂脚9个月未复发！阿布昔替尼效果真实案例 3.新药价格：2026年特皮外用/口服/针剂药物医保最新价格 4.科普资讯 : 特应性皮炎（湿疹）是遗传吗？用度普利尤/司普奇拜等药是否能根治? 参考文献： 1.康诺亚2025年度业绩报告 2.康诺亚公告，司普奇拜单抗纳入医保信息，2026年1月 3.国家医保药品目录（2025年版） 4.Stapokibart III期临床试验数据 5.度普利尤单抗说明书及上市后研究数据 6.康诺亚官网新闻中心 7.2026年特应性皮炎药物医保价格汇总本文仅做参考，不提供任何诊疗意见，不构成对任何药物的推广或宣传，如有任何问题，请前往医院向专业医师咨询。部分材料和图片源于网络，侵删欢迎大家多多分享转发~

2026-03-31
·伊顿健康资讯

特皮吃乌帕替尼6年，会产生抗体药效下降吗？长期用药安全性数据解读

伊顿健康导读：特应性皮炎是个磨人的慢性病。很多病友都经历过这样的循环：用药→好转→停药→复发→再用药。当医生告诉你"可能需要长期吃乌帕替尼"时，心里难免打鼓——吃6年，身体扛得住吗？药效会越来越差吗？会不会产生抗体？一、6年数据出炉，安全性怎么样？最近，一项覆盖2683名患者、随访长达6年的乌帕替尼长期安全性研究正式发布。这是目前JAK抑制剂在特应性皮炎领域最长时间的随访数据。先说结论：整体安全性稳定，没有发现新的风险信号。具体来看： l 严重不良事件：15mg组6.6例/100患者年，30mg组7.4例/100患者年，两组相近 l 主要心血管不良事件（MACE）：15mg组0.2例/100患者年，30mg组<0.1例/100患者年 l 静脉血栓栓塞（VTE）：两组均为0.1例/100患者年 l 恶性肿瘤（不含非黑色素瘤皮肤癌）：15mg组0.3例/100患者年，30mg组0.5例/100患者年 l 淋巴瘤：两组均<0.1例/100患者年最值得关注的是：这些发生率并未随用药时间延长而上升，6年间保持稳定。这意味着，吃这个药不会因为吃久了就累积风险。二、吃久了会产生抗体吗？药效会下降吗？这是很多患者担心的问题。首先要区分两个概念：抗体耐药和疗效衰减。 l 关于抗体：乌帕替尼是小分子JAK抑制剂，不是生物制剂（如度普利尤单抗那种大分子抗体药）。小分子药物通常不会诱导机体产生中和抗体，这是它与生物制剂的重要区别。 l 关于疗效：研究显示，乌帕替尼的疗效在长达76周的治疗中保持稳定甚至持续改善。Measure Up研究中，52周时EASI 90应答率维持在80%左右，没有明显的"药效减退"现象。当然，临床上确实有少数患者反馈"吃久了感觉效果不如从前"，这可能与疾病本身的波动、依从性、或合并用药有关，而非真正的耐药。如果确实疗效下降，建议及时复诊评估，而不是自行加量或停药。三、15mg还是30mg？怎么选？研究也给出了明确指导：剂量相关的不良事件主要包括：带状疱疹、肝酶升高、中性粒细胞减少、肌酸激酶升高。30mg组这些事件发生率确实略高于15mg组，但绝对数值仍处于低水平。临床决策建议以疗效为导向： l 皮损重、瘙痒剧烈、急需快速控制的患者，可考虑30mg l 病情相对稳定、或存在心血管风险因素的患者，15mg可能是更稳妥的选择重要的是，不必因担心安全性而牺牲疗效。正如研究作者Bunick教授所说，长期数据已经提供了安全保障，医生可以根据患者的具体需求灵活选择剂量。四、日常监测怎么做？不需要过度检查。基线检查完成后，每3-6个月复查一次即可，重点关注： l 血常规（监测中性粒细胞） l 肝肾功能 l 血脂（30mg组需更关注）另外，接种带状疱疹疫苗是皮肤科医生可以主动采取的重要措施。研究中仅不到5%的患者接种了疫苗，而带状疱疹是JAK抑制剂已知的风险之一。你在吃乌帕替尼吗？遇到过什么困惑？欢迎在评论区聊聊。伊顿健康结语 1.阿布昔替尼口服混悬剂III期（乌帕替尼同靶点药），国内外已上市（950元），研究周期16周。治疗后有机会使用阿布昔替尼参加长期2年扩展研究。 2.长森药业LW402片（乌帕替尼同靶点药） III期临床，用药一年。伊顿健康平台为大家争取优惠用药福利价格和相关生物制剂的临床用药（符合临床条件，用药体检由项目组承担，不额外对患者收费费用，有可观补贴）了解更多资讯添加工作人员参加临床项目直接报名参考文献： 1.Bunick CG, et al. Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years. J Eur Acad Dermatol Venereol. 2025. PMID: 41239921 2.Guttman-Yassky E, et al. Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials. JAMA Dermatol. 2022;158(4):404-411 3.中国中西医结合学会皮肤性病专业委员会. 系统Janus激酶抑制剂治疗特应性皮炎专家共识. 2023 4.特应性皮炎治疗药物临床试验技术指导原则. 国家药监局. 2022 本文仅做参考，不构成对任何药物或诊疗方案的推荐、推广或宣传，也不可替代专业医疗建议。如有问题，请咨询医疗卫生专业人士。材料图片等源自网络，侵删。点击下方关注我们的鼻肺专属平台

临床结果临床研究

2026-03-30
·allsci.com

Sanofi’s amlitelimab meets Phase III endpoints in atopic dermatitis with extended 12-week dosing interval

Sanofi (NASDAQ: SNY) reported Phase III data from three trials of amlitelimab in moderate-to-severe atopic dermatitis, showing that the anti-OX40L antibody met primary endpoints across monotherapy and combination settings — with efficacy at a dosing interval of once every 12 weeks that matched the every-four-week regimen. The results, presented as late-breaking research at the 2026 American Academy of Dermatology annual meeting in Denver, position amlitelimab as a mechanistically distinct entrant into a treatment landscape that has grown crowded but remains defined by frequent dosing and incomplete responses. The COAST 1 and COAST 2 trials were randomized, double-blind, placebo-controlled Phase III studies evaluating amlitelimab monotherapy in adults and adolescents aged 12 and older with moderate-to-severe atopic dermatitis. SHORE used the same design but tested amlitelimab in combination with topical corticosteroids, with or without topical calcineurin inhibitors. Across the three trials, 1,786 patients were enrolled at sites spanning North America, Europe, Asia, and Latin America. The primary endpoint for all three studies was the proportion of patients achieving a validated Investigator Global Assessment for atopic dermatitis (vIGA-AD) score of 0 or 1 — clear or almost clear skin — with at least a two-point reduction from baseline at Week 24. Both the Q4W and Q12W amlitelimab arms met this endpoint in each trial.For US and US reference countries, the primary endpoint was vIGA-AD 0/1 with a ≥2-point reduction. Of note, for the EU reference countries and Japan, the studies used co-primary endpoints that included the same vIGA-AD measure plus EASI-75. In COAST 1, vIGA-AD 0/1 rates were 21.1% (Q4W) and 22.5% (Q12W) versus 9.2% for placebo. EASI-75 — the proportion of patients achieving at least 75% improvement in the Eczema Area and Severity Index — reached 35.9% and 39.1% in the Q4W and Q12W arms, respectively, compared to 19.1% for placebo. Itch reduction, measured by a four-point or greater decrease in peak pruritus numerical rating scale, was 22.5% (Q4W) and 24.5% (Q12W) versus 12.7% for placebo. All key secondary endpoints in COAST 1 reached statistical significance. COAST 2 showed a similar pattern, with vIGA-AD 0/1 rates of 25.3% (Q4W) and 25.7% (Q12W) versus 14.8% for placebo. EASI-75 and itch endpoints reached nominal significance, though one secondary endpoint — vIGA-AD 0/1 with barely perceptible erythema — did not achieve statistical significance. The distinction between the two monotherapy trials is worth noting: COAST 2’s higher placebo response rate narrowed the treatment delta, a common challenge in atopic dermatitis trials with geographically diverse enrollment. SHORE, the combination study, produced the highest absolute response rates. vIGA-AD 0/1 was achieved by 28.7% (Q4W) and 32.3% (Q12W) of patients versus 16.8% on placebo plus topical therapy alone. EASI-75 reached 48.1% and 46.8% in the active arms versus 32.3% for placebo. All primary and key secondary endpoints were statistically significant. Across all three trials, Sanofi reported that efficacy was progressively increasing at Week 24 with no evidence of plateau, suggesting that longer treatment durations may yield higher response rates — a pattern that will be tested in the ongoing ESTUARY extension study. The safety profile was consistent with earlier-phase data. The most common adverse events across COAST 1, COAST 2, and SHORE were nasopharyngitis, atopic dermatitis flares, and upper respiratory tract infections, occurring at rates generally comparable to or lower than placebo. Malignancy rates were below 1% and similar between active and placebo groups. No severe injection site reactions or serious gastrointestinal ulceration events were reported. Sanofi disclosed a second case of Kaposi’s sarcoma in the amlitelimab development program, identified in the still-blinded ESTUARY Phase III extension study. Both Kaposi’s sarcoma cases occurred in patients with known risk factors, and both patients discontinued treatment and entered recovery. Out of an estimated 3,778 patients exposed to amlitelimab across all indications, no additional cases have been identified. The signal remains numerically small but warrants monitoring given the immunomodulatory mechanism. Sanofi stated that it “believes that amlitelimab continues to have the potential to be a meaningful and convenient option for patients with AD”. Amlitelimab is a fully human, non-T cell depleting monoclonal antibody that blocks OX40 ligand, a costimulatory molecule involved in the activation and survival of effector T cells. By targeting this upstream pathway, the drug aims to modulate pathogenic immune responses without the broad immunosuppression associated with JAK inhibitors or the cytokine-specific blockade of IL-4/IL-13 antibodies. The non-depleting design distinguishes it from therapies that reduce T cell populations, potentially offering a different safety-efficacy tradeoff. The atopic dermatitis treatment landscape in 2026 includes six approved systemic therapies for moderate-to-severe disease: dupilumab and tralokinumab (both anti-IL-4/IL-13 pathway), lebrikizumab (anti-IL-13), nemolizumab (anti-IL-31 receptor), and the oral JAK1 inhibitors abrocitinib and upadacitinib. All approved injectable biologics require dosing every two to four weeks. Amlitelimab’s Q12W regimen — approximately four injections per year — would represent a substantial reduction in treatment burden if the dosing schedule is maintained in regulatory filings. Cross-trial comparisons are limited by differences in study populations, placebo rates, and endpoint definitions, but the absolute vIGA-AD 0/1 and EASI-75 rates observed in the COAST and SHORE trials are numerically lower than those reported for dupilumab and upadacitinib in their respective pivotal programs. Whether the dosing convenience and mechanistic novelty offset the apparent efficacy gap will be a central question for regulators, payers, and prescribers. Rocatinlimab, developed by Amgen, targets the OX40 receptor rather than the ligand and is also in Phase III development for atopic dermatitis. The two drugs represent competing approaches to the same pathway, and their relative clinical profiles will become clearer as more data emerge. A 2024 review in the Journal of Dermatology and Therapy examined both molecules, noting that while they share a pathway target, their binding sites and downstream effects may differ. Results from ESTUARY, evaluating Q12W maintenance dosing and longer-term safety, are anticipated in the second half of 2026. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

临床结果临床3期免疫疗法

100 项与阿布昔替尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11400	阿布昔替尼	D11AH	DB14973

研发状态

批准上市

10 条最早获批的记录,
登录
后查看更多信息

适应症	国家/地区	公司	日期
特应性皮炎	英国	Pfizer Inc.	2021-09-08

未上市

10 条进展最快的记录,
登录
后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
湿疹	临床3期	美国	Pfizer Inc.	2018-06-11
湿疹	临床3期	中国	Pfizer Inc.	2018-06-11
湿疹	临床3期	阿根廷	Pfizer Inc.	2018-06-11
湿疹	临床3期	比利时	Pfizer Inc.	2018-06-11
湿疹	临床3期	巴西	Pfizer Inc.	2018-06-11
湿疹	临床3期	保加利亚	Pfizer Inc.	2018-06-11
湿疹	临床3期	加拿大	Pfizer Inc.	2018-06-11
湿疹	临床3期	智利	Pfizer Inc.	2018-06-11
湿疹	临床3期	德国	Pfizer Inc.	2018-06-11
湿疹	临床3期	以色列	Pfizer Inc.	2018-06-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03575871 \| NCT03422822 \| NCT03349060 \| NCT03796676 \| NCT03627767 (JADE MONO-1, MONO-2, TEEN, REGIMEN, EXTEND, Pubmed \| Allergy)	临床3期	中度特应性皮炎	-	Abrocitinib 200mg	構鹽網鹽憲積夢積餘蓋(鑰範齋網築鏇壓範襯鑰) = 繭齋選鏇構鹹構膚窪願構鹹構繭襯網鹽糧築積 (繭範膚範鑰艱餘觸鑰願 ) 更多	积极	2025-08-01
				Abrocitinib 100mg	構鹽網鹽憲積夢積餘蓋(鑰範齋網築鏇壓範襯鑰) = 鹽鑰觸衊範積選簾獵網構鹹構繭襯網鹽糧築積 (繭範膚範鑰艱餘觸鑰願 ) 更多
AHEAD (NEWS) 人工标引	N/A	特应性皮炎	-	阿布昔替尼 (未接受过其他系统治疗)	齋蓋遞襯簾選鏇夢簾鏇(艱願襯糧遞獵簾齋築鬱) = 選觸鹽醖築遞築鑰遞鏇蓋網壓餘鏇蓋製艱齋廠 (築醖繭夢襯網範顧網顧 )	积极	2025-06-27
				阿布昔替尼 (既往接受过系统治疗)	齋蓋遞襯簾選鏇夢簾鏇(艱願襯糧遞獵簾齋築鬱) = 獵製選窪糧壓積簾簾壓蓋網壓餘鏇蓋製艱齋廠 (築醖繭夢襯網範顧網顧 )
ChiCTR2200063195 (Pubmed) 人工标引	N/A	特应性皮炎	117	Abrocitinib	顧廠膚獵襯鑰製獵網遞(選網範鹹襯繭夢範構膚) = 壓襯窪鑰鑰餘膚衊繭糧積襯築遞夢製鑰築膚顧 (積艱醖膚鏇齋襯願構構 ) 更多	积极	2025-05-01
NCT03349060 (JADE MONO-1, AAD2025)	临床3期	特应性皮炎	-	Abrocitinib 200 mg	觸廠餘齋築衊鏇廠顧齋(齋繭鑰糧選構醖壓積積) = 鬱網廠網衊鏇積選鹹構衊獵蓋顧鏇艱選繭衊繭 (積簾窪淵繭壓齋觸餘齋 ) 更多	积极	2025-03-07
				Abrocitinib 100 mg	觸廠餘齋築衊鏇廠顧齋(齋繭鑰糧選構醖壓積積) = 艱衊憲窪蓋繭淵窪糧選衊獵蓋顧鏇艱選繭衊繭 (積簾窪淵繭壓齋觸餘齋 ) 更多
NCT03422822 (JADE EXTEND, AAD2025)	临床3期	斑秃 \| 特应性皮炎	71	Abrocitinib 200 mg	製夢衊繭蓋鏇選簾壓顧(艱醖壓鏇獵糧膚膚遞積) = 2 patients (31-year-old White male [previously reported] and 38-year-old White male) treated with consistent-dose abrocitinib 200 mg and 2 patients (42- and 49-year-old White males) in the variable-dose cohort reported an AE of hair growth/regrowth. Greater proportions of patients treated with consistent-dose abrocitinib 200 mg versus 100 mg achieved Week 12 IGA 0/1 (44% [11/25] vs 25% [3/12]), EASI-75 (61% [19/31] vs 25% [3/12]), and PP-NRS4 (56% [15/27] vs 22% [2/9]). Abrocitinib improved itch and skin clearance in substantial proportions of patients with AD and comorbid AA; hair growth/regrowth was reported in 4 patients. 糧觸築製鹹鏇繭積夢蓋 (製繭範網廠獵鑰獵淵鑰 )	积极	2025-03-07
				Abrocitinib 100 mg
NCT03349060 (JADE MONO-1, AAD2025)	临床3期	特应性皮炎	2,082	Abrocitinib 100 mg	製顧鑰廠簾觸網選襯廠(顧築窪鏇襯膚築鏇餘廠) = 鹹蓋憲廠繭壓積餘淵繭餘積獵膚艱艱淵簾願壓 (獵簾艱襯鹽願糧糧襯網 ) 更多	积极	2025-03-07
				Abrocitinib 200 mg	壓襯齋遞獵繭蓋構壓鏇(襯齋繭鹽餘餘積範鏇鏇) = 鹽壓鹽遞顧壓範衊淵醖築蓋鏇積鹽築繭膚齋鏇 (齋齋鹹蓋鹹繭築簾齋構 ) 更多
NCT04345367 (JADE DARE, AAD2025)	临床3期	中度特应性皮炎	727	Abrocitinib 200 mg	築顧顧衊襯糧襯簾簾壓(醖壓觸鹹憲鹹夢鹹鑰積) = 鹹築構膚繭範鏇艱網鏇構繭願夢範廠鬱範鹹觸 (鬱構鹽鏇淵選鬱範齋糧, 0.5 ~ 0.9)	积极	2025-03-07
				Dupilumab 300 mg	築顧顧衊襯糧襯簾簾壓(醖壓觸鹹憲鹹夢鹹鑰積) = 積築遞淵淵構蓋簾構衊構繭願夢範廠鬱範鹹觸 (鬱構鹽鏇淵選鬱範齋糧, 0.2 ~ 0.7)
AAD2025	N/A	特应性皮炎	123	tralokinumab	積網衊範襯襯鑰廠壓鏇(壓選構齋蓋淵糧夢鹹簾) = 獵遞膚選構鹽憲築積積襯廠範膚鬱願積鏇餘鹹 (願築襯壓鹽襯鑰糧築繭 ) 更多	积极	2025-03-07
				abrocitinib	積網衊範襯襯鑰廠壓鏇(壓選構齋蓋淵糧夢鹹簾) = 壓遞製鬱遞壓淵鹹鏇鏇襯廠範膚鬱願積鏇餘鹹 (願築襯壓鹽襯鑰糧築繭 ) 更多
AAD2025	N/A	重度特应性皮炎	530	Upadacitinib	鏇糧衊願壓遞壓醖糧選(壓鑰範壓築鹽簾觸鏇淵) = 淵築範餘衊餘醖鏇醖艱觸繭選艱餘夢鏇顧衊齋 (淵壓鹹夢遞餘壓鹹蓋蓋 ) 更多	积极	2025-03-07
				Baricitinib	鏇糧衊願壓遞壓醖糧選(壓鑰範壓築鹽簾觸鏇淵) = 繭糧積醖網獵顧憲顧獵觸繭選艱餘夢鏇顧衊齋 (淵壓鹹夢遞餘壓鹹蓋蓋 ) 更多
NCT05375929 (CTgov)	临床3期	中度特应性皮炎 \| 重度特应性皮炎	200	Abrocitinib (Main Study: Abrocitinib 200 mg)	齋衊範構艱襯糧鏇築襯 = 觸製膚製鹹襯簾獵醖廠衊築襯積選壓鬱夢簾淵 (廠艱壓醖淵顧夢範製繭, 繭繭顧窪廠壓遞築鏇網 ~ 築鹽網顧糧願夢襯遞蓋) 更多	-	2024-09-19
				Abrocitinib (Main Study: Abrocitinib 100 mg)	齋衊範構艱襯糧鏇築襯 = 醖鬱網襯衊遞窪夢窪範衊築襯積選壓鬱夢簾淵 (廠艱壓醖淵顧夢範製繭, 簾壓廠鹽鏇夢鑰築夢獵 ~ 鹽網獵鏇夢鑰網壓窪壓) 更多

登录后查看更多信息

转化医学

使用我们的转化医学数据加速您的研究。

或

查看完整样例数据

药物交易

使用我们的药物交易数据加速您的研究。

或

查看完整样例数据

核心专利

使用我们的核心专利数据促进您的研究。

或

查看完整样例数据

临床分析

紧跟全球注册中心的最新临床试验。

或

查看完整样例数据

批准

利用最新的监管批准信息加速您的研究。

或

查看完整样例数据

特殊审评

只需点击几下即可了解关键药物信息。

或

查看完整样例数据

生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用

化学结构数据库
小分子化药研发创新
免费使用